The effects of neoadjuvant therapy on morbidity and mortality of esophagectomy for esophageal cancer: American college of surgeons national surgical quality improvement program (ACS–NSQIP) 2005–2012

Michel J. Sabra, Carmen Smotherman, D. Kraemer, Michael S. Nussbaum, Joseph J. Tepas, Ziad T. Awad

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: This study used a multi-center database to evaluate the impact of neoadjuvant therapy on the 30-day morbidity and mortality following esophagectomy for esophageal cancer. Methods: The NSQIP database was queried for 2005–2012 for patients, who had esophagectomy for esophageal cancer. Patients were divided into two groups: neoadjuvant therapy and esophagectomy only. Results: The neoadjuvant group had a lower rates of sepsis (8% vs. 13%, unadjusted P = 0.004) and acute renal failure (0.4% vs. 2%, unadjusted P = 0.01), and a higher rate of pulmonary embolism (PE) (3% vs. 1%, unadjusted P = 0.04). The adjusted odds of PE for patients, who received neoadjuvant therapy were 2.8 times the odds of PE for patients in the esophagectomy group, controlling for BMI. The association with renal failure was not significant, when one adjusted for race. There was no difference in the rates of reoperation, readmission, stroke, cardiac arrest, MI, surgical site and deep organ infections, anastomosis failure, blood transfusions, DVT, septic shock, pneumonia, UTI, respiratory failure, and 30-day mortality between the two groups. Conclusions: We conclude that neoadjuvant therapy followed by esophagectomy for esophageal cancer does not have a negative impact on 30-day mortality. Neoadjuvant therapy is associated with increased odds of PE. J. Surg. Oncol. 2017;115:296–300.

Original languageEnglish
Pages (from-to)296-300
Number of pages5
JournalJournal of Surgical Oncology
Volume115
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Neoadjuvant Therapy
Esophagectomy
Esophageal Neoplasms
Quality Improvement
Pulmonary Embolism
Morbidity
Mortality
Databases
Septic Shock
Group Psychotherapy
Heart Arrest
Reoperation
Acute Kidney Injury
Blood Transfusion
Respiratory Insufficiency
Renal Insufficiency
Sepsis
Pneumonia
Stroke
Surgeons

Keywords

  • esophageal cancer
  • neoadjuvant therapy
  • NSQIP
  • outcome

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

The effects of neoadjuvant therapy on morbidity and mortality of esophagectomy for esophageal cancer : American college of surgeons national surgical quality improvement program (ACS–NSQIP) 2005–2012. / Sabra, Michel J.; Smotherman, Carmen; Kraemer, D.; Nussbaum, Michael S.; Tepas, Joseph J.; Awad, Ziad T.

In: Journal of Surgical Oncology, Vol. 115, No. 3, 01.03.2017, p. 296-300.

Research output: Contribution to journalArticle

@article{c04de2d6eacb43b595b106d3233c4bc7,
title = "The effects of neoadjuvant therapy on morbidity and mortality of esophagectomy for esophageal cancer: American college of surgeons national surgical quality improvement program (ACS–NSQIP) 2005–2012",
abstract = "Objective: This study used a multi-center database to evaluate the impact of neoadjuvant therapy on the 30-day morbidity and mortality following esophagectomy for esophageal cancer. Methods: The NSQIP database was queried for 2005–2012 for patients, who had esophagectomy for esophageal cancer. Patients were divided into two groups: neoadjuvant therapy and esophagectomy only. Results: The neoadjuvant group had a lower rates of sepsis (8{\%} vs. 13{\%}, unadjusted P = 0.004) and acute renal failure (0.4{\%} vs. 2{\%}, unadjusted P = 0.01), and a higher rate of pulmonary embolism (PE) (3{\%} vs. 1{\%}, unadjusted P = 0.04). The adjusted odds of PE for patients, who received neoadjuvant therapy were 2.8 times the odds of PE for patients in the esophagectomy group, controlling for BMI. The association with renal failure was not significant, when one adjusted for race. There was no difference in the rates of reoperation, readmission, stroke, cardiac arrest, MI, surgical site and deep organ infections, anastomosis failure, blood transfusions, DVT, septic shock, pneumonia, UTI, respiratory failure, and 30-day mortality between the two groups. Conclusions: We conclude that neoadjuvant therapy followed by esophagectomy for esophageal cancer does not have a negative impact on 30-day mortality. Neoadjuvant therapy is associated with increased odds of PE. J. Surg. Oncol. 2017;115:296–300.",
keywords = "esophageal cancer, neoadjuvant therapy, NSQIP, outcome",
author = "Sabra, {Michel J.} and Carmen Smotherman and D. Kraemer and Nussbaum, {Michael S.} and Tepas, {Joseph J.} and Awad, {Ziad T.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1002/jso.24493",
language = "English",
volume = "115",
pages = "296--300",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - The effects of neoadjuvant therapy on morbidity and mortality of esophagectomy for esophageal cancer

T2 - American college of surgeons national surgical quality improvement program (ACS–NSQIP) 2005–2012

AU - Sabra, Michel J.

AU - Smotherman, Carmen

AU - Kraemer, D.

AU - Nussbaum, Michael S.

AU - Tepas, Joseph J.

AU - Awad, Ziad T.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objective: This study used a multi-center database to evaluate the impact of neoadjuvant therapy on the 30-day morbidity and mortality following esophagectomy for esophageal cancer. Methods: The NSQIP database was queried for 2005–2012 for patients, who had esophagectomy for esophageal cancer. Patients were divided into two groups: neoadjuvant therapy and esophagectomy only. Results: The neoadjuvant group had a lower rates of sepsis (8% vs. 13%, unadjusted P = 0.004) and acute renal failure (0.4% vs. 2%, unadjusted P = 0.01), and a higher rate of pulmonary embolism (PE) (3% vs. 1%, unadjusted P = 0.04). The adjusted odds of PE for patients, who received neoadjuvant therapy were 2.8 times the odds of PE for patients in the esophagectomy group, controlling for BMI. The association with renal failure was not significant, when one adjusted for race. There was no difference in the rates of reoperation, readmission, stroke, cardiac arrest, MI, surgical site and deep organ infections, anastomosis failure, blood transfusions, DVT, septic shock, pneumonia, UTI, respiratory failure, and 30-day mortality between the two groups. Conclusions: We conclude that neoadjuvant therapy followed by esophagectomy for esophageal cancer does not have a negative impact on 30-day mortality. Neoadjuvant therapy is associated with increased odds of PE. J. Surg. Oncol. 2017;115:296–300.

AB - Objective: This study used a multi-center database to evaluate the impact of neoadjuvant therapy on the 30-day morbidity and mortality following esophagectomy for esophageal cancer. Methods: The NSQIP database was queried for 2005–2012 for patients, who had esophagectomy for esophageal cancer. Patients were divided into two groups: neoadjuvant therapy and esophagectomy only. Results: The neoadjuvant group had a lower rates of sepsis (8% vs. 13%, unadjusted P = 0.004) and acute renal failure (0.4% vs. 2%, unadjusted P = 0.01), and a higher rate of pulmonary embolism (PE) (3% vs. 1%, unadjusted P = 0.04). The adjusted odds of PE for patients, who received neoadjuvant therapy were 2.8 times the odds of PE for patients in the esophagectomy group, controlling for BMI. The association with renal failure was not significant, when one adjusted for race. There was no difference in the rates of reoperation, readmission, stroke, cardiac arrest, MI, surgical site and deep organ infections, anastomosis failure, blood transfusions, DVT, septic shock, pneumonia, UTI, respiratory failure, and 30-day mortality between the two groups. Conclusions: We conclude that neoadjuvant therapy followed by esophagectomy for esophageal cancer does not have a negative impact on 30-day mortality. Neoadjuvant therapy is associated with increased odds of PE. J. Surg. Oncol. 2017;115:296–300.

KW - esophageal cancer

KW - neoadjuvant therapy

KW - NSQIP

KW - outcome

UR - http://www.scopus.com/inward/record.url?scp=84996844001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996844001&partnerID=8YFLogxK

U2 - 10.1002/jso.24493

DO - 10.1002/jso.24493

M3 - Article

C2 - 27813095

AN - SCOPUS:84996844001

VL - 115

SP - 296

EP - 300

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -